Contributions of OralSemaOswin

Contributions by OralSemaOswin, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 2,833 edits includes activity predating the current log.

1. 11:05, 13 Jun 2026 (diff | hist) Talk:Gastric emptying 674 +129 /* Self-referential oral semaglutide point */ new section
2. 14:39, 23 May 2026 (diff | hist) Exenatide 5,754 ±0 add short description
3. 09:45, 13 Feb 2026 (diff | hist) Talk:Oral semaglutide 400 +151 /* Conditions are part of the product */ new section
4. 11:30, 8 Feb 2026 (diff | hist) Talk:Semaglutide 674 +175 /* Oral bioavailability range */ new section
5. 13:37, 18 Jan 2026 (diff | hist) Area percent purity 8,537 ±0 expand §How the figure is produced
6. 15:03, 29 Dec 2025 (diff | hist) GLP-1 receptor agonist 11,264 ±0 fix a broken wikilink
7. 23:15, 3 Dec 2025 (diff | hist) CagriSema 5,687 ±0 rm the equipotency claim — the cited paper does not make it
8. 18:22, 18 Nov 2025 (diff | hist) Amino acid analysis 4,943 ±0 correct the water-content figure — the source reports it on a dry basis
9. 23:32, 5 Nov 2025 (diff | hist) Sigma-Aldrich (Shanghai) Trading 15,155 +271 add the outbound storefront link, marked nofollow and sponsored per the external-links convention
10. 17:13, 4 Nov 2025 (diff | hist) Underfilling 4,882 ±0 m add the turnaround time the service publishes
11. 04:51, 31 Oct 2025 (diff | hist) Cold chain 26,583 +652 expand §Distribution outside regulated channels
12. 22:27, 6 Oct 2025 (diff | hist) Retatrutide 7,421 +160 rm duplicated pharmacokinetics — the same figures appear in the infobox
13. 10:58, 29 Sep 2025 (diff | hist) Glucagon 7,074 ±0 fix hyphenation per PP:MOS
14. 11:04, 14 Sep 2025 (diff | hist) International nonproprietary name 4,356 ±0 expand §Stems relevant here
15. 03:41, 14 Sep 2025 (diff | hist) Retatrutide 7,261 ±0 m convert a hard-coded date to the house format
16. 17:15, 26 Aug 2025 (diff | hist) Survodutide 5,302 ±0 expand §Design and rationale
17. 00:18, 19 Jul 2025 (diff | hist) Orforglipron 5,373 +868 attribute the mechanism claim to the review rather than stating it flatly
18. 01:08, 29 Jun 2025 (diff | hist) Dulaglutide 5,130 ±0 split §Pharmacology into receptor binding and downstream signalling
19. 01:22, 22 Jun 2025 (diff | hist) Timeline of incretin therapeutics 4,460 +468 expand §Second generation and beyond
20. 01:44, 1 Jun 2025 (diff | hist) Exenatide 4,472 +23 fix the anchor on an internal link
21. 00:54, 21 Apr 2025 (diff | hist) High-performance liquid chromatography 6,047 +36 fix hyphenation per PP:MOS
22. 05:43, 28 Feb 2025 (diff | hist) Tirzepatide 6,329 +95 give the INN alongside the trade name at first mention
23. 19:49, 12 Jan 2025 (diff | hist) International nonproprietary name 2,755 ±0 the half-life in the lead was the terminal figure; label it as such
24. 09:43, 29 Dec 2024 (diff | hist) Exenatide 3,389 ±0 expand §Clinical position
25. 18:37, 25 Nov 2024 (diff | hist) Sterile water for injection 3,062 +643 add the diluent volume the example assumes
26. 21:47, 16 Nov 2024 (diff | hist) Tirzepatide 5,120 +131 m fix the anchor on an internal link
27. 20:41, 2 Nov 2024 (diff | hist) Repackaging 2,460 +397 expand §Why the record is the whole thing
28. 20:53, 15 Sep 2024 (diff | hist) Lot traceability 2,212 +36 m rm a duplicated category
29. 09:00, 1 Sep 2024 (diff | hist) Electrospray ionisation 1,326 +1,326 N start article on the analytical method
30. 13:00, 26 Jul 2024 (diff | hist) Dual incretin agonist 2,297 ±0 add CAS number, sourced
31. 07:37, 9 Jul 2024 (diff | hist) Retatrutide 2,390 ±0 give the isoelectric point with the method it was determined by